On November 23, 2022, Renhaim Inc. participated in GBIF 2022 (Global Bio Investment Forum 2022) held at Lotte Hotel in Sogongdong, Seoul, and introduced its corporate IR (Investor Relations). Renhaim CEO Taejin Kang introduced main technologies and projects of company and revealed his aspirations to establish a new mRNA-based drug development platform. The event was attended by prominent national investors and companies.
We are thrilled to bring you the latest updates from our research and development front, where the spotlight is on the revolutionary mRNA technology. This cutting-edge technology, propelled into the limelight during the COVID-19 pandemic, is proving to be a game-changer in healthcare.
The versatility of mRNA technology has been a hope in the fight against infectious diseases. Beyond its rapid response capabilities, We are harnessing this innovative platform for groundbreaking advancements in healthcare.
Our primary focus is on leveraging mRNA technology to address the fundamental causes of osteoarthritis. We are on a mission to develop a treatment that not only slows the progression of osteoarthritis but fundamentally transforms the way we approach and manage this prevalent condition.
For more details, please refer to the link below.
